Regula Naresh, Häggman Michael, Johansson Silvia, Sörensen Jens
Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Section of Urology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2131-2138. doi: 10.1007/s00259-016-3449-7. Epub 2016 Jul 8.
Malignant de novo lipogenesis is strongly linked to the aggressiveness of prostate cancer (PCa) under experimental conditions. C-Acetate PET/CT is a potential noninvasive biomarker of malignant lipogenesis in PCa, but its prognostic value is not known. The objective of this study was to analyse C-acetate PET/CT image metrics in relation to survival.
All patients undergoing C-acetate PET/CT in one university hospital from 2005 to 2011 due to PSA relapse after previous prostatectomy were retrospectively evaluated. Two groups of patients were compared: those who died from PCa and those who were censored. All previously reported findings of local recurrence, regional or distal lymph node metastases and bone metastases were counted and evaluated regarding C-acetate uptake intensity (SUV) and tumour volume. Total tumour volume and total lipogenic activity (TLA, summed SUV × TV) were calculated. Survival analysis in the entire study population was followed by Cox proportional hazards ratio (HR) analysis.
A total of 121 patients were included, and 22 PCa-specific deaths were recorded. The mean PSA level at the time of PET was 2.69 ± 4.35 ng/mL. The median follow-up of the study population was 79 ± 28 months. PET identified at least one PCa lesion in 53 % of patients. Five-year PCa-specific survival after PET was 80 % and 100 % in patients with a positive and a negative PET scan, respectively (p < 0.001). Time-to-death was linearly correlated with highest SUV (r = -0.55, p = 0.01) and nonlinearly with TLA (r = -0.75, p < 0.001). Multivariate analysis showed statistical significance for number of bone metastases (HR 1.74, p = 0.01), tertile of TLA (HR 5.63, p = 0.029) and postoperative Gleason score (HR 1.84, p = 0.045).
Malignant C-acetate accumulation measured with PET/CT is a strong predictor of survival in the setting of PSA relapse after prostatectomy. The study provides further evidence for a quantitative relationship between malignant de novo lipogenesis and early death. C-Acetate PET/CT might be useful for identifying a high-risk population of relapsing patients in which therapies targeting malignant lipogenesis might be of particular benefit.
在实验条件下,恶性新生脂肪生成与前列腺癌(PCa)的侵袭性密切相关。碳-醋酸盐正电子发射断层扫描/计算机断层扫描(C-醋酸盐PET/CT)是PCa中恶性脂肪生成的一种潜在非侵入性生物标志物,但其预后价值尚不清楚。本研究的目的是分析与生存相关的C-醋酸盐PET/CT图像指标。
对2005年至2011年在一家大学医院因先前前列腺切除术后PSA复发而接受C-醋酸盐PET/CT检查的所有患者进行回顾性评估。比较两组患者:死于PCa的患者和被审查的患者。对所有先前报告的局部复发、区域或远处淋巴结转移以及骨转移的结果进行计数,并根据C-醋酸盐摄取强度(SUV)和肿瘤体积进行评估。计算总肿瘤体积和总脂肪生成活性(TLA,SUV总和×TV)。在整个研究人群中进行生存分析,随后进行Cox比例风险比(HR)分析。
共纳入121例患者,记录到22例PCa特异性死亡。PET检查时的平均PSA水平为2.69±4.35 ng/mL。研究人群的中位随访时间为79±28个月。PET在53%的患者中发现至少一个PCa病变。PET检查后,PET阳性和阴性患者的5年PCa特异性生存率分别为80%和100%(p<0.001)。死亡时间与最高SUV呈线性相关(r=-0.55,p=0.01),与TLA呈非线性相关(r=-0.75,p<0.001)。多变量分析显示骨转移数量(HR 1.74,p=0.01)、TLA三分位数(HR 5.63,p=0.029)和术后Gleason评分(HR 1.84,p=0.045)具有统计学意义。
PET/CT测量的恶性C-醋酸盐积聚是前列腺切除术后PSA复发情况下生存的有力预测指标。该研究为恶性新生脂肪生成与早期死亡之间的定量关系提供了进一步证据。C-醋酸盐PET/CT可能有助于识别复发患者的高危人群,在这些人群中,针对恶性脂肪生成的治疗可能特别有益。